Key points are not available for this paper at this time.
Design
Case report
Metastatic Ewing sarcoma confers ~30% survival; leaves open need for novel therapies targeting extrapulmonary disease.
Ewing's sarcoma (ES) of bone is a highly aggressive cancer typically diagnosed in childhood and adolescence, with a survival of 70% to 80% for patients with standard-risk and localized disease and ∼30% for those with metastatic disease.1 In fact, the key adverse prognostic factor is the presence of metastases at the time of diagnosis,2 especially for extrapulmonary metastases.3 It has been shown that sites of primary and metastatic tumors differ according to age. Young children (0-9 years) show significantly fewer primary tumors at axial sites (especially fewer pelvic tumors), and they have a significantly higher proportion of smaller tumors.
No takes yet. Share an insight, caveat, or question.
Mejías et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Advances in Radiation Oncology